Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02824224 · ClinicalTrials.gov registry record · Phase 4
Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)
A Phase 4 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
NCT02824224 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 42 participants.
The verdict
NCT02824224, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study evaluates the ability of tamoxifen to improve frequent or prolonged bleeding in new users of the 52mg levonorgestrel-releasing intrauterine device (IUD). Half of participants will receive a course of tamoxifen three weeks after insertion of the IUD, while the other half of participants will receive a course of placebo.
Interventions
- DRUG Tamoxifen
- DRUG Placebo (for Tamoxifen)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-09-06 |
| Est. Completion | 2018-01-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02824224
The ClinicalTrials.gov registry entry for NCT02824224 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT02824224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02824224 about?
NCT02824224 is a clinical study titled "Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)". This study evaluates the ability of tamoxifen to improve frequent or prolonged bleeding in new users of the 52mg levonorgestrel-releasing intrauterine device (IUD). Half of participants will receive a course of tamoxifen three weeks after insertion of the IUD, while the other half of participants wi...
What is the current status of trial NCT02824224?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2016-09-06. Estimated completion is 2018-01-08.
What interventions are being tested in trial NCT02824224?
The interventions under investigation include: Tamoxifen (DRUG), Placebo (for Tamoxifen) (DRUG).
Who is sponsoring clinical trial NCT02824224?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.